Disease Overview
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.
ATG16L1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| ADALIMUMAB | ? unclear | Mechanistic | DGIdb |
FOXP3
IL10
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| EFAVIRENZ | ? unclear | Mechanistic | DGIdb | |
| ANESTHETIC AGENT | ? unclear | Mechanistic | DGIdb | |
| ACYCLOVIR | ? unclear | Mechanistic | DGIdb | |
| MACROLIDE ANTIBIOTIC | ? unclear | Mechanistic | DGIdb | |
| LISOFYLLINE | ? unclear | Mechanistic | DGIdb | |
| PROTON PUMP INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| SCH-708980 | ↓ inhibits | Mechanistic | DGIdb | |
| SIROLIMUS | ? unclear | Mechanistic | DGIdb | |
| SHO-SAIKO-TO | ? unclear | Mechanistic | DGIdb | |
| RABEPRAZOLE | ? unclear | Mechanistic | DGIdb | |
| AMOXICILLIN ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| CLARITHROMYCIN | ? unclear | Mechanistic | DGIdb | |
| ILODECAKIN | ? unclear | Mechanistic | DGIdb | |
| FLUTICASONE | ? unclear | Mechanistic | DGIdb | |
| TRETINOIN | ? unclear | Mechanistic | DGIdb | |
| MESALAMINE | ? unclear | Mechanistic | DGIdb | |
| ROFECOXIB | ? unclear | Mechanistic | DGIdb | |
| ETANERCEPT | ? unclear | Mechanistic | DGIdb | |
| PEGILODECAKIN | ? unclear | Mechanistic | DGIdb | |
| ZIDOVUDINE | ? unclear | Mechanistic | DGIdb |
IL12B
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| TILDRAKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| EGEN-001 | ? unclear | Mechanistic | DGIdb | |
| USTEKINUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| BRAZIKUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| GUSELKUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| BRIAKINUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| ISOPROTERENOL | ? unclear | Mechanistic | DGIdb | |
| EBDAROKIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| HUMANIZED SMART ANTI-IL-12 ANTIBODY | ? unclear | Mechanistic | DGIdb | |
| ADENOVIRAL TRANSDUCED HIL-12-EXPRESSING AUTOLOGOUS DENDRITIC CELLS INXN-3001 PLUS ACTIVATOR LIGAND INXN-1001 | ? unclear | Mechanistic | DGIdb | |
| VIRULIZIN | ? unclear | Mechanistic | DGIdb | |
| RISANKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| MIRIKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| INFLIXIMAB | ? unclear | Mechanistic | DGIdb |
IL23A
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| USTEKINUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| RISANKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| MIRIKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| BRAZIKUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| TILDRAKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| GUSELKUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| EBDAROKIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| BRIAKINUMAB | ↓ inhibits | Mechanistic | DGIdb |
IL23R
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| INFLIXIMAB | ? unclear | Mechanistic | DGIdb | |
| AZATHIOPRINE | ? unclear | Mechanistic | DGIdb | |
| CELECOXIB | ? unclear | Mechanistic | DGIdb | |
| CHEMBL4206167 | ↓ inhibits | Mechanistic | 1.81 nM (Kd) | ChEMBL |
| CHEMBL4567228 | ↓ inhibits | Mechanistic | 113.0 nM (IC50) | ChEMBL |
| CHEMBL4555885 | ↓ inhibits | Mechanistic | 32.0 nM (IC50) | ChEMBL |
| CHEMBL4529484 | ↓ inhibits | Mechanistic | 25.0 nM (IC50) | ChEMBL |
| CHEMBL4577218 | ↓ inhibits | Mechanistic | 39.0 nM (IC50) | ChEMBL |
| CHEMBL4442232 | ↓ inhibits | Mechanistic | 892.0 nM (IC50) | ChEMBL |
| CHEMBL4565015 | ↓ inhibits | Mechanistic | 37.0 nM (IC50) | ChEMBL |
| CHEMBL4515769 | ↓ inhibits | Mechanistic | 199.0 nM (IC50) | ChEMBL |
| CHEMBL4451305 | ↓ inhibits | Mechanistic | 79.0 nM (IC50) | ChEMBL |
| CHEMBL4441983 | ↓ inhibits | Mechanistic | 220.0 nM (IC50) | ChEMBL |
| CHEMBL4537768 | ↓ inhibits | Mechanistic | 102.0 nM (IC50) | ChEMBL |
| CHEMBL4458363 | ↓ inhibits | Mechanistic | 78.0 nM (IC50) | ChEMBL |
| CHEMBL4454287 | ↓ inhibits | Mechanistic | 183.0 nM (IC50) | ChEMBL |
| CHEMBL4452903 | ↓ inhibits | Mechanistic | 57.0 nM (IC50) | ChEMBL |
| CHEMBL4457621 | ↓ inhibits | Mechanistic | 52.0 nM (IC50) | ChEMBL |
| CHEMBL4543753 | ↓ inhibits | Mechanistic | 518.0 nM (IC50) | ChEMBL |
| CHEMBL4527549 | ↓ inhibits | Mechanistic | 153.0 nM (IC50) | ChEMBL |
| CHEMBL4540496 | ↓ inhibits | Mechanistic | 223.0 nM (IC50) | ChEMBL |
| CHEMBL4524632 | ↓ inhibits | Mechanistic | 79.0 nM (IC50) | ChEMBL |
| CHEMBL4459265 | ↓ inhibits | Mechanistic | 124.0 nM (IC50) | ChEMBL |
| CHEMBL4550853 | ↓ inhibits | Mechanistic | 2584.0 nM (IC50) | ChEMBL |
| CHEMBL4435141 | ↓ inhibits | Mechanistic | 30000.0 nM (IC50) | ChEMBL |
| CHEMBL4446365 | ↓ inhibits | Mechanistic | 100.0 nM (IC50) | ChEMBL |
| CHEMBL4462185 | ↓ inhibits | Mechanistic | 96.0 nM (IC50) | ChEMBL |
| CHEMBL4454702 | ↓ inhibits | Mechanistic | 99.0 nM (IC50) | ChEMBL |
| CHEMBL4576008 | ↓ inhibits | Mechanistic | 95.0 nM (IC50) | ChEMBL |
| CHEMBL4589681 | ↓ inhibits | Mechanistic | 107.0 nM (IC50) | ChEMBL |
| CHEMBL4583420 | ↓ inhibits | Mechanistic | 101.0 nM (IC50) | ChEMBL |
| CHEMBL4440544 | ↓ inhibits | Mechanistic | 107.0 nM (IC50) | ChEMBL |
| CHEMBL4564118 | ↓ inhibits | Mechanistic | 47.0 nM (IC50) | ChEMBL |
| CHEMBL4537038 | ↓ inhibits | Mechanistic | 59.0 nM (IC50) | ChEMBL |
| CHEMBL4547985 | ↓ inhibits | Mechanistic | 206.0 nM (IC50) | ChEMBL |
| CHEMBL4558328 | ↓ inhibits | Mechanistic | 40.0 nM (IC50) | ChEMBL |
| CHEMBL4567670 | ↓ inhibits | Mechanistic | 139.0 nM (IC50) | ChEMBL |
| CHEMBL4582731 | ↓ inhibits | Mechanistic | 1885.0 nM (IC50) | ChEMBL |
| CHEMBL4435308 | ↓ inhibits | Mechanistic | 134.0 nM (IC50) | ChEMBL |
| CHEMBL4564607 | ↓ inhibits | Mechanistic | 48.0 nM (IC50) | ChEMBL |
Showing top 40 of 178 agents ranked by evidence tier.
ITGA4
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| SENKTIDE | ? unclear | Mechanistic | DGIdb | |
| VEDOLIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| R1295 | ? unclear | Mechanistic | DGIdb | |
| ABRILUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| UCB-1184197 | ↓ inhibits | Mechanistic | DGIdb | |
| ATL1102 | ? unclear | Mechanistic | DGIdb | |
| NATALIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| FIRATEGRAST | ↓ inhibits | Mechanistic | DGIdb | |
| BIO1211 | ? unclear | Mechanistic | DGIdb |
JAK1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| RUXOLITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| IZENCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| PEMBROLIZUMAB | ? unclear | Mechanistic | DGIdb | |
| RUXOLITINIB PHOSPHATE | ↓ inhibits | Mechanistic | DGIdb | |
| GOLIDOCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| FILGOTINIB MALEATE | ↓ inhibits | Mechanistic | DGIdb | |
| MOMELOTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| AZD1480 | ↓ inhibits | Mechanistic | DGIdb | |
| DELGOCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| TRICETAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| TOFACITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| PEFICITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| BREPOCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| UPADACITINIB HEMIHYDRATE | ↓ inhibits | Mechanistic | DGIdb | |
| CYCLOSPORINE | ? unclear | Mechanistic | DGIdb | |
| INCB-047986 | ↓ inhibits | Mechanistic | DGIdb | |
| ABROCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| ENZASTAURIN | ? unclear | Mechanistic | DGIdb | |
| CERDULATINIB | ↓ inhibits | Mechanistic | DGIdb | |
| NEZULCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| FILGOTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| GLPG-0555 | ↓ inhibits | Mechanistic | DGIdb | |
| SOLCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| GUSACITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| ITACITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| BARICITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE | ? unclear | Mechanistic | Open Targets | |
| DEURUXOLITINIB PHOSPHATE | ? unclear | Mechanistic | Open Targets | |
| TOFACITINIB CITRATE | ? unclear | Mechanistic | Open Targets | |
| UPADACITINIB | ? unclear | Mechanistic | Open Targets |
JAK2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| TYRPHOSTIN 23 | ? unclear | Mechanistic | DGIdb | |
| AZD1480 | ↓ inhibits | Mechanistic | DGIdb | |
| PF-562271 | ? unclear | Mechanistic | DGIdb | |
| JAK2V617F INHIBITOR INCB160058 | ? unclear | Mechanistic | DGIdb | |
| PEMBROLIZUMAB | ? unclear | Mechanistic | DGIdb | |
| TOFACITINIB | ↓ inhibits | Mechanistic | 11.0 nM (IC50) | DGIdb |
| RUXOLITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| FEDRATINIB | ↓ inhibits | Mechanistic | DGIdb | |
| TENALISIB | ? unclear | Mechanistic | DGIdb | |
| FILGOTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| PACRITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| BARICITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| NS-018 | ↓ inhibits | Mechanistic | DGIdb | |
| TANESPIMYCIN | ? unclear | Mechanistic | DGIdb | |
| AZD1208 | ? unclear | Mechanistic | DGIdb | |
| PICTILISIB | ? unclear | Mechanistic | DGIdb | |
| DOVITINIB | ? unclear | Mechanistic | 7000.0 nM (Kd) | DGIdb |
| AZ960 | ? unclear | Mechanistic | DGIdb | |
| GANDOTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2B | ? unclear | Mechanistic | DGIdb | |
| LUMINESPIB | ? unclear | Mechanistic | DGIdb | |
| ROPEGINTERFERON ALFA-2B | ? unclear | Mechanistic | DGIdb | |
| MOMELOTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| AZD-1480 | ↓ inhibits | Mechanistic | DGIdb | |
| NEZULCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| TYRPHOSTIN AG 555 | ? unclear | Mechanistic | DGIdb | |
| GELDANAMYCIN | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL546797 | ? unclear | Mechanistic | DGIdb | |
| ERLOTINIB | ? unclear | Mechanistic | 4000.0 nM (IC50) | DGIdb |
| BINIMETINIB | ? unclear | Mechanistic | DGIdb | |
| PD-0166285 | ? unclear | Mechanistic | DGIdb | |
| SGI-1776 | ? unclear | Mechanistic | DGIdb | |
| XL-019 | ↓ inhibits | Mechanistic | DGIdb | |
| THIRAM | ? unclear | Mechanistic | DGIdb | |
| RIBOCICLIB | ? unclear | Mechanistic | DGIdb | |
| ALFENTANIL HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL29197 | ? unclear | Mechanistic | DGIdb | |
| CEP-11981 | ? unclear | Mechanistic | DGIdb | |
| DACTOLISIB | ? unclear | Mechanistic | DGIdb | |
| AT-9283 | ↓ inhibits | Mechanistic | 1.2 nM (IC50) | DGIdb |
Showing top 40 of 256 agents ranked by evidence tier.
MADCAM1
NOD2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| INARIGIVIR SOPROXIL | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1351908 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL585502 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL577660 | ? unclear | Mechanistic | DGIdb | |
| MICROPARTICLE MDP/BACTERIAL DNA-CONTAINING MIS416 | ? unclear | Mechanistic | DGIdb | |
| CYCLOVALONE | ? unclear | Mechanistic | 9950.0 nM (EC50) | DGIdb |
| CHEMBL:CHEMBL1456848 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL599890 | ? unclear | Mechanistic | DGIdb | |
| MIFAMURTIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL578944 | ? unclear | Mechanistic | DGIdb | |
| MURABUTIDE | ? unclear | Mechanistic | DGIdb | |
| ANHYDROUS TACROLIMUS | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL590706 | ? unclear | Mechanistic | DGIdb | |
| CYCLOSPORINE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL1542558 | ↓ inhibits | Mechanistic | 16600.0 nM (IC50) | ChEMBL |
| CHEMBL1717353 | ↓ inhibits | Mechanistic | 8440.0 nM (IC50) | ChEMBL |
| CHEMBL1373066 | ↓ inhibits | Mechanistic | 17300.0 nM (IC50) | ChEMBL |
| CHEMBL1586616 | ↓ inhibits | Mechanistic | 3990.0 nM (IC50) | ChEMBL |
| CHEMBL1708503 | ↓ inhibits | Mechanistic | 1720.0 nM (IC50) | ChEMBL |
| CHEMBL1312200 | ↓ inhibits | Mechanistic | 7040.0 nM (IC50) | ChEMBL |
| CHEMBL599890 | ↓ inhibits | Mechanistic | 19700.0 nM (IC50) | ChEMBL |
| CHEMBL1561275 | ↓ inhibits | Mechanistic | 5900.0 nM (IC50) | ChEMBL |
| CHEMBL1405985 | ↓ inhibits | Mechanistic | 2930.0 nM (IC50) | ChEMBL |
| CHEMBL1543504 | ↓ inhibits | Mechanistic | 5900.0 nM (IC50) | ChEMBL |
| CHEMBL1710033 | ↓ inhibits | Mechanistic | 1620.0 nM (IC50) | ChEMBL |
| CHEMBL1729430 | ↓ inhibits | Mechanistic | 7930.0 nM (IC50) | ChEMBL |
| CHEMBL1519375 | ↓ inhibits | Mechanistic | 16900.0 nM (IC50) | ChEMBL |
| CHEMBL1388356 | ↓ inhibits | Mechanistic | 17800.0 nM (IC50) | ChEMBL |
| CHEMBL1700643 | ↓ inhibits | Mechanistic | 15300.0 nM (IC50) | ChEMBL |
| CHEMBL1719980 | ↓ inhibits | Mechanistic | 19000.0 nM (IC50) | ChEMBL |
| CHEMBL1314048 | ↓ inhibits | Mechanistic | 11700.0 nM (IC50) | ChEMBL |
| CHEMBL1508723 | ↓ inhibits | Mechanistic | 6080.0 nM (IC50) | ChEMBL |
| CHEMBL1542483 | ↓ inhibits | Mechanistic | 9140.0 nM (IC50) | ChEMBL |
| CHEMBL1599782 | ↓ inhibits | Mechanistic | 12000.0 nM (IC50) | ChEMBL |
| CHEMBL1491541 | ↓ inhibits | Mechanistic | 11400.0 nM (IC50) | ChEMBL |
| CHEMBL1712022 | ↓ inhibits | Mechanistic | 18500.0 nM (IC50) | ChEMBL |
| CHEMBL1529494 | ↓ inhibits | Mechanistic | 8210.0 nM (IC50) | ChEMBL |
| CHEMBL1299637 | ↓ inhibits | Mechanistic | 2160.0 nM (IC50) | ChEMBL |
| CHEMBL1426966 | ↓ inhibits | Mechanistic | 6900.0 nM (IC50) | ChEMBL |
| CHEMBL1731774 | ↓ inhibits | Mechanistic | 1120.0 nM (IC50) | ChEMBL |
Showing top 40 of 202 agents ranked by evidence tier.
S1PR1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CHEMBL:CHEMBL171699 | ? unclear | Mechanistic | DGIdb | |
| (S)-FTY720P | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1362503 | ? unclear | Mechanistic | DGIdb | |
| SAR247799 | ? unclear | Mechanistic | DGIdb | |
| ASP-4058 | ? unclear | Mechanistic | DGIdb | |
| MOCRAVIMOD HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| BMS-986104 | ? unclear | Mechanistic | DGIdb | |
| PONESIMOD | ↑ activates | Mechanistic | DGIdb | |
| ISOVELLERAL | ? unclear | Mechanistic | DGIdb | |
| SIPONIMOD | ↑ activates | Mechanistic | DGIdb | |
| AMISELIMOD HYDROCHLORIDE | ~ modulates | Mechanistic | DGIdb | |
| GSK-2018682 | ? unclear | Mechanistic | DGIdb | |
| FINGOLIMOD LAURYL SULFATE | ~ modulates | Mechanistic | DGIdb | |
| FINGOLIMOD HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL586135 | ? unclear | Mechanistic | DGIdb | |
| OZANIMOD HYDROCHLORIDE | ~ modulates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL579318 | ? unclear | Mechanistic | DGIdb | |
| KRP203 | ↑ activates | Mechanistic | DGIdb | |
| AMISELIMOD | ? unclear | Mechanistic | DGIdb | |
| CENERIMOD | ~ modulates | Mechanistic | DGIdb | |
| 9,10-PHENANTHRENEQUINONE | ? unclear | Mechanistic | DGIdb | |
| ETRASIMOD ARGININE | ~ modulates | Mechanistic | DGIdb | |
| ETRASIMOD | ↑ activates | Mechanistic | DGIdb | |
| SIPONIMOD FUMARIC ACID | ↑ activates | Mechanistic | DGIdb | |
| OZANIMOD | ? unclear | Mechanistic | DGIdb | |
| FINGOLIMOD | ? unclear | Mechanistic | DGIdb | |
| SONEPCIZUMAB | ? unclear | Mechanistic | DGIdb | |
| PINAFIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL117910 | ↓ inhibits | Mechanistic | 1.4 nM (IC50) | ChEMBL |
| CHEMBL332050 | ↑ activates | Mechanistic | 82.0 nM (EC50) | ChEMBL |
| CHEMBL115505 | ↑ activates | Mechanistic | 322.1 nM (EC50) | ChEMBL |
| CHEMBL115344 | ↑ activates | Mechanistic | 260.0 nM (EC50) | ChEMBL |
| CHEMBL324358 | ↑ activates | Mechanistic | 598.4 nM (EC50) | ChEMBL |
| CHEMBL332472 | ↑ activates | Mechanistic | 12.7 nM (EC50) | ChEMBL |
| CHEMBL422074 | ↑ activates | Mechanistic | 58.0 nM (EC50) | ChEMBL |
| CHEMBL225155 | ↑ activates | Mechanistic | 0.9 nM (EC50) | ChEMBL |
| CHEMBL116953 | ↑ activates | Mechanistic | 130.0 nM (EC50) | ChEMBL |
| CHEMBL334038 | ↑ activates | Mechanistic | 8.6 nM (EC50) | ChEMBL |
| CHEMBL325408 | ↑ activates | Mechanistic | 1805.0 nM (EC50) | ChEMBL |
| CHEMBL114031 | ↑ activates | Mechanistic | 550.0 nM (EC50) | ChEMBL |
Showing top 40 of 211 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| NERELIMOMAB | ↓ inhibits | Mechanistic | DGIdb | |
| CROMOLYN SODIUM | ? unclear | Mechanistic | DGIdb | |
| PLACULUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| METHYLENE BLUE | ? unclear | Mechanistic | DGIdb | |
| ALTEPLASE | ? unclear | Mechanistic | DGIdb | |
| CARBOPLATIN | ? unclear | Mechanistic | DGIdb | |
| GENTAMICIN | ? unclear | Mechanistic | DGIdb | |
| GOLIMUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| BUPIVACAINE | ? unclear | Mechanistic | DGIdb | |
| PENTOXIFYLLINE | ? unclear | Mechanistic | DGIdb | |
| BENZO[E]PYRENE | ? unclear | Mechanistic | DGIdb | |
| THALIDOMIDE | ? unclear | Mechanistic | DGIdb | |
| PYRAZINAMIDE | ? unclear | Mechanistic | DGIdb | |
| GLIMEPIRIDE | ? unclear | Mechanistic | DGIdb | |
| OMEPRAZOLE | ? unclear | Mechanistic | DGIdb | |
| LENERCEPT | ↓ inhibits | Mechanistic | DGIdb | |
| ADALIMUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| PRAZOSIN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| REMTOLUMAB | ? unclear | Mechanistic | DGIdb | |
| MIDOSTAURIN | ? unclear | Mechanistic | DGIdb | |
| LENABASUM | ? unclear | Mechanistic | DGIdb | |
| MAGNESIUM SULFATE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| PICIBANIL | ? unclear | Mechanistic | DGIdb | |
| FLUOCINOLONE ACETONIDE | ? unclear | Mechanistic | DGIdb | |
| MILTEFOSINE | ? unclear | Mechanistic | DGIdb | |
| HOMIDIUM BROMIDE | ? unclear | Mechanistic | DGIdb | |
| OZORALIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| PEGSUNERCEPT | ↓ inhibits | Mechanistic | DGIdb | |
| CERTOLIZUMAB PEGOL | ↓ inhibits | Mechanistic | DGIdb | |
| THERAPEUTIC HORMONE | ? unclear | Mechanistic | DGIdb | |
| NAFAMOSTAT | ? unclear | Mechanistic | DGIdb | |
| FOLIC ACID | ? unclear | Mechanistic | DGIdb | |
| ABBV-257 | ? unclear | Mechanistic | DGIdb | |
| RISPERIDONE | ? unclear | Mechanistic | DGIdb | |
| COVA322 | ? unclear | Mechanistic | DGIdb | |
| HYDROXYCHLOROQUINE | ? unclear | Mechanistic | DGIdb | |
| CERTOLIZUMAB | ? unclear | Mechanistic | DGIdb | |
| AN0128 | ? unclear | Mechanistic | DGIdb | |
| 5,7-DIHYDROXY-4-METHYLCOUMARIN | ? unclear | Mechanistic | DGIdb | |
| SORAFENIB | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 91 agents ranked by evidence tier.
TYK2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| LORPUCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| FILGOTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| RG-1530 | ? unclear | Mechanistic | DGIdb | |
| ZOTIRACICLIB | ↓ inhibits | Mechanistic | DGIdb | |
| SAR-20347 | ↓ inhibits | Mechanistic | DGIdb | |
| DEUCRAVACITINIB | ~ modulates | Mechanistic | DGIdb | |
| CERDULATINIB | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 6 [PMID: 34333981] | ↓ inhibits | Mechanistic | DGIdb | |
| RUXOLITINIB | ↓ inhibits | Mechanistic | 19.0 nM (IC50) | DGIdb |
| OCLACITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| GDC-0214 | ↓ inhibits | Mechanistic | DGIdb | |
| JNJ-7706621 | ? unclear | Mechanistic | 32.0 nM (Kd) | DGIdb |
| BREPOCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| IZENCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| 2-TERT-BUTYL-9-FLUORO-1,6-DIHYDROBENZO[H]IMIDAZO[4,5-F]ISOQUINOLIN-7-ONE | ↓ inhibits | Mechanistic | DGIdb | |
| PF-562271 | ? unclear | Mechanistic | DGIdb | |
| UPADACITINIB HEMIHYDRATE | ↓ inhibits | Mechanistic | DGIdb | |
| JAK3 INHIBITOR 34 | ↓ inhibits | Mechanistic | DGIdb | |
| UPADACITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| DOVITINIB | ? unclear | Mechanistic | 150.0 nM (Kd) | DGIdb |
| ROPSACITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| GOLIDOCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 13AC [PMID: 33256400] | ↓ inhibits | Mechanistic | DGIdb | |
| TYK2 INHIBITOR 18 [WO2023227946] | ~ modulates | Mechanistic | DGIdb | |
| TAMATINIB | ? unclear | Mechanistic | DGIdb | |
| CYC-116 | ? unclear | Mechanistic | 79.43 nM (Ki) | DGIdb |
| PF-06263276 | ↓ inhibits | Mechanistic | DGIdb | |
| GO-6976 | ? unclear | Mechanistic | DGIdb | |
| SJ988497 | ? unclear | Mechanistic | DGIdb | |
| PEFICITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| NVP-TAE684 | ? unclear | Mechanistic | DGIdb | |
| COMPOUND 25AP [PMID: 37796543] | ↓ inhibits | Mechanistic | DGIdb | |
| HESPERADIN | ↓ inhibits | Mechanistic | 75.0 nM (Kd) | DGIdb |
| COMPOUND 29 [MOSLIN ET AL., 2017] | ↓ inhibits | Mechanistic | DGIdb | |
| ALDESLEUKIN | ? unclear | Mechanistic | DGIdb | |
| BMS-986202 | ↓ inhibits | Mechanistic | DGIdb | |
| SOLCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| MOMELOTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| FEDRATINIB | ↓ inhibits | Mechanistic | 150.0 nM (IC50) | DGIdb |
| BMS-911543 | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 216 agents ranked by evidence tier.
Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-03.
The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits. Additional treatment may be available to participants via a Continu...
The main aim of this study is to learn about medical problems (adverse events) if vedolizumab subcutaneously (SC) is given to a child or teenager with UC or CD for a long time. Other aims are to understand if the long time use of vedolizumab SC has an impact on the time period until hospital visits ...
A Phase 1, 2-part, randomised, double-blind, placebo-controlled, FIH study to determine the safety, tolerability, and PK of single, ascending oral doses (SAD) of BDHK-2009 (Part 1) and multiple oral doses (Part 2) of BDHK-200 in healthy adult participants.
The goal of this observational study is to learn about how effective Zymfentra (IFX=dyyb) is when treating patients with Crohn's disease (CD) and ulcerative colitis (UC) Does Zymfentra lead to a reduction in symptoms at intervals throughout one year? Participants being prescribed Zymfentra (IFX-dyyb...
Crohn's Disease and Ulcerative Colitis are two types of inflammatory bowel disease (IBD), which is a serious, long-term condition in the gut (intestine) that can cause pain and swelling (inflammation) in the bowel. TAK-279 is a medicine which helps to block inflammation. This study is an extension ...
The purpose of this study is to determine the safety profile of long-term vedolizumab IV treatment in pediatric participants with UC or CD.
Healthcare contributes approximately 4.4% of global GHG emissions, with diagnostic imaging and endoscopic services being substantial contributors. Colonoscopy and cross-sectional imaging modalities, though indispensable, are associated with high carbon emissions due to electricity use, waste, steril...
The study is an extension of two parent studies (MLN0002-3024 \[NCT04779307\] and MLN0002-3025 \[NCT04779320\]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.
The primary reason of this study is to observe current treatment options in participants receiving Vedolizumab, intravenous (IV) or subcutaneous (SC), for IBD in Poland. There is no treatment involved in this study, this is only an observational review of ongoing/initiating treatment data relating t...
This study is a randomized controlled clinical trial evaluating whether two therapeutic dietary approaches - a ketogenic diet and a carnivore (lion) diet - can improve quality of life, reduce symptoms, and influence measures of disease activity in adults with inflammatory bowel disease \[ulcerative ...
This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.
This comparative observational cohort clinical study aims to investigate the necessity of premedication for allergy prevention prior to infliximab injection, and is designed to evaluate whether non-routine administration of dexamethasone before intravenous infusion of infliximab yields greater benef...
The purpose of the study is determine if a plant-based resistant starch that is optimized for the individual will target the underlying cause of inflammatory bowel disease and restore a "healthier" gut microbiome in pediatric participants with inflammatory bowel disease.
This clinical study protocol aims to prospectively compare the efficacy of standard therapy with anti-TNF agents combined with the Crohn's Disease Exclusion Diet (CDED) versus anti-TNF therapy alone in adult patients with active Crohn's disease or ulcerative colitis. The study will involve patients...
The investigators are doing the research to discover genes that cause Inflammatory Bowel Disease (IBD) specifically in the African American population. African Americans with or without Crohn's disease or ulcerative colitis are eligible to join. If you agree to join the study, the investigators will...
Searched directly from “Inflammatory Bowel Disease (Crohn's/UC)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 14-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
28 agents shown (approved or with trial evidence) — 22 not found by the gene-target search above.
Vedolizumab
· 4 trials · source: ClinicalTrials.gov
NCT03196427 NCT03138655 NCT07273760
Anti-TNF TherapyNOT in gene-target list
· 2 trials · source: ClinicalTrials.gov
NCT03090139 NCT06896305
Mirikizumab
· 2 trials · source: ClinicalTrials.gov
NCT04844606 NCT04844606
Fecal Microbiota Transplantation (FMT)NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT02108821
Upadacitinib
· 1 trial · source: ClinicalTrials.gov
NCT06922331
Ustekinumab 90 mg SC q8wNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT07303686
Ustekinumab 90 mg SC q12wNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT07303686
Risankizumab
· 1 trial · source: ClinicalTrials.gov
NCT04254783
Cytochrome P450 (CYP) SubstratesNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT04254783
Vedolizumab IVNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT05442567
PF2020-CELL (UC-MSCs) - Allogeneic Human Umbilical Cord Mesenchymal Stem CellsNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT05039411
Vitamin D3NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT01877577
Multispectral Optoacoustic Tomography (MSOT)NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT04650867
Ketogenic dietNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT07524244
Carnivore (Lion) DietNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT07524244
Zasocitinib
· 1 trial · source: ClinicalTrials.gov
NCT06764615
Adalimumab
· 1 trial · source: ClinicalTrials.gov
NCT04089514
Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samplesNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT01364896
Dexamethasone (IV)NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT07385131
InflectraNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT03801928
MT-501NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT07113522
MT-201NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT07113522
CDED (Crohn's Disease Exclusion Diet) in addition to anti-TNF therapyNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT06896305
UTTR1147ANOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT02749630
BDHK-2009 TabletsNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT07632573
Vedolizumab SCNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT06405087
AB (antibiotics)NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT02033408
CS (corticosteroids) OnlyNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT02033408